At the news
? BEARISHIMPACT 8/10 PRESS-RELEASE filed May 12, 2026 at 07:05 ET
Arvinas reported Q1 2026 revenue of $15.6M (down 91.7% YoY from $188.8M) and a GAAP EPS of -$0.90, significantly missing the consensus estimate of -$0.63. The revenue collapse was driven by the removal of two Phase 3 trials from the Pfizer collaboration plan, which had inflated prior-year revenue. While the FDA approval of VEPPANU (first-ever PROTAC) and its out-licensing to Rigel are transformative milestones, the severe revenue decline and EPS miss dominate the near-term narrative.
- Q1 2026 revenue of $15.6M vs $188.8M YoY, a 91.7% decline due to changes in Pfizer collaboration cost estimates
- GAAP EPS of -$0.90 vs consensus -$0.63, a 42.9% miss
- Cash burn of $67.5M in operations during Q1; cash position $614.9M, sufficient into 2H 2028
- FDA approval of VEPPANU (vepdegestrant) as first-ever PROTAC therapy for ER+/HER2- breast cancer
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access